What is Catheter Precision Inc.?
designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States.
VTAK · Verdict
Solid reward · elevated risk
VTAK stands out on volatility and growth, but watch the cash flow signal.
Based on 88% data coverage
VTAK · Verdict
Above average
Rev +167.3% CAGR · earnings -12.8%
-2223% free-cash-flow margin
-3963% net margin · -185% ROE
Model-based scoring. For information only — not financial advice.
designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The company is listed on the NYSE MKT in USA, operating in the Healthcare sector, with a market capitalisation of 3.05M, and a P/E ratio of 0.1x.
The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.